28 results about "Antithrombotic" patented technology

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The present application relates to the field of food, health care products and medicine, and specifically relates to a purslane oral composition for regulating blood lipid and resisting atherosclerosis, and a preparation method and application thereof. The present application takes purslane extract, galangal extract and borneol as core components, and realizes the synergistic effects of lipid regulation, anti-inflammation, reduction of plaque area, stabilization of vulnerable plaque, mild anti-thrombus and myocardial protection through scientific proportioning. The bioavailability is significantly improved by combining the tongue sublingual absorption of borneol and the mucosal penetration of galangal volatile oil. The composition has comprehensive targets, definite effects and good safety, and can be made into oral dosage forms such as buccal tablets, dripping pills and oral disintegrating tablets, and is suitable for daily oral care of cardiovascular sub-healthy people.

The present application relates to the technical field of biology, and discloses a cell preservation solution, a preparation method and preparation thereof, and a cell preservation method. The cell preservation solution contains 1-10 mL compound electrolyte glucose injection, 1-10 mL human blood albumin injection, 1-10 mL compound amino acid injection, 10-20 uM salvianolic acid B, 20-60 uM rhodioside, and 1-10 uM ginkgo biloba bilobal, and the compound electrolyte injection is supplemented. The cell preservation solution can improve the biological activity of cells and prolong the preservation time of cells in multiple ways by adding traditional Chinese medicine extracts as antioxidants, membrane stabilizers and antithrombotics in response to the excess of free radicals in the low-temperature preservation process.

This application discloses a wearable anti-thrombotic pressure pump detection system and its control method, belonging to the field of thrombosis technology. The detection system includes a limb sleeve, a blood flow detector, a vascular injury detector, a pressure pump assembly, a pressure sensor, and a processor. The limb sleeve can be easily worn on the patient's body. The blood flow detector is used to detect the blood flow velocity in the patient's body, and the vascular injury detector is used to detect whether there is damage to the blood vessels in the patient's body. The pressure sensor is used to detect the working pressure output by the pressure pump assembly, and the processor can automatically adjust the working pressure output by the pressure pump assembly according to the initial settings. The detection system disclosed in this invention utilizes the pressure sensor to detect the working pressure output by the pressure pump assembly in real time. When the working pressure output by the pressure pump assembly exceeds the safe value, the processor can quickly send an adjustment command to the pressure pump assembly, thereby ensuring that the working pressure output by the pressure pump assembly is continuously maintained within the safe range.

This invention provides a traditional Chinese medicine compound preparation and its application in the preparation of drugs for treating cardiovascular and cerebrovascular diseases, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine compound preparation comprises the following raw materials in parts by weight: 10-20 parts bee pollen, 8-15 parts curcumin, 5-10 parts γ-aminobutyric acid, 5-12 parts Litsea cubeba leaf, 10-20 parts hawthorn, 5-10 parts Lindera strychnifolia leaf, 10-20 parts kudzu root, 5-12 parts ginseng, 8-15 parts Polygonatum sibiricum, 6-12 parts Sophora japonica flower bud, 3-8 parts tangerine peel, and 1-5 parts L-cysteine. This invention significantly improves the water solubility, stability, and bioavailability of curcumin by constructing a chlorophyll zinc / LDH nanosheet composite carrier to load curcumin. A compound preparation of traditional Chinese medicine was prepared by combining a complex loaded with curcumin with various food and medicine homologous ingredients. This traditional Chinese medicine compound preparation can significantly reduce whole blood viscosity, plasma viscosity and platelet aggregation rate in rats with acute blood stasis model, has anti-thrombotic effect, and significantly promotes the recovery of neurological function in rats with focal cerebral ischemia and reduces the volume of cerebral infarction.

Provided is an antithrombotic coating material containing a polyorganosiloxane having at least one of an oxiranyl group and an oxetanyl group, thereby forming a coating film having excellent adhesion to a substrate while exhibiting good antithrombotic properties.

This invention relates to a heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity, its preparation method, and its application, belonging to the field of biomedical technology. The heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity comprises an AT-binding sequence and a -GlcNS(6S)-GlcA2S- or -GlcNS(6S)-IdoA2S- linker sequence, specifically heparin anticoagulant dodecanosaccharide 12I-2, heparin anticoagulant dodecanosaccharide 12G-1, or heparin anticoagulant dodecanosaccharide 12G-2. This invention also provides methods for preparing heparin anticoagulant dodecanosaccharides 12I-2, 12G-1, and 12G-2, and their applications in the preparation of safe and effective anticoagulant and antithrombotic drugs. The heparin anticoagulant oligosaccharide designed in this invention is a specific dodecanoic acid molecule. By optimizing its sugar chain length, key structural domains and spatial conformation, its ability to form pathogenic H / PF4 complexes with platelet factor 4 (PF4) is weakened to the greatest extent. In clinical anticoagulation applications, it has a significant safety advantage in reducing the incidence of HIT and related fatal thrombosis (HITT).

This invention relates to the fields of enzyme engineering and bioactive peptide preparation technology, and discloses a method for preparing equine cardiac muscle peptides with antioxidant and antithrombotic effects, comprising the following steps: S1: Pre-treating equine heart tissue to obtain equine cardiac muscle plasma; S2: Compound enzymatic hydrolysis and directing agent regulation: Adding a compound enzyme system and an antithrombotic directing agent to the equine cardiac muscle plasma; S3: Affinity chromatography enrichment. This invention constructs a synergistic process of compound enzymatic hydrolysis, directing regulation, and affinity enrichment, specifically addressing the technical problems of incomplete tissue fragmentation, low enzymatic hydrolysis efficiency, insufficient yield of active peptides, and easy oxidative inactivation in equine cardiac muscle due to the high proportion of type IIa myofibrous fibers and dense connective tissue. Furthermore, it employs a specific ratio of compound enzyme system adapted to the characteristics of equine cardiac muscle, significantly improving enzymatic hydrolysis efficiency; introduces a cationic directing agent to directionally increase the proportion of antithrombotic peptides generated; and combines thrombin affinity chromatography to achieve efficient enrichment of target peptides, significantly enhancing antithrombotic function while ensuring high antioxidant activity.

The application provides a multifunctional nano-coated stent for preventing and treating in-stent restenosis and a preparation method and application thereof. Based on the multifunctional nano interface of EGCG-Cys, the liposome targeting VCAM-1 is used to deliver MnO2 nanoscale enzyme and FGF21 growth factor, so that the triple treatment effects of active oxygen scavenging, immune regulation and endothelial regeneration can be realized at the vascular lesion site. The EC-MFVL-WE43 stent creates a new paradigm for the design of interventional instruments, realizes the spatiotemporal precise release of drugs through the oxidative stress triggered degradation mechanism, and verifies the excellent anti-restenosis and anti-thrombosis performance in mouse, rabbit and pig models. Mechanism research shows that the nano-coated stent can reprogram macrophages to M2 repair type polarization, and effectively inhibit the abnormal proliferation of smooth muscle cells, providing a biological activity solution to break the vicious cycle of "inflammation-oxidation-restenosis".

This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its enantiomer, diastereomer, transtransferase, racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain protein of Src kinase, interfering with the binding of integrin αIIbβ3 to Src kinase, thereby selectively inhibiting outward-to-inward signal transduction without affecting inward-to-outward signal transduction. This allows the compound of this invention to exert antithrombotic effects without affecting normal physiological hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of thrombosis-related cardiovascular and cerebrovascular diseases.

This invention provides an antithrombotic polymer, its preparation method, and its applications. The antithrombotic polymer consists of three parts: A) fibrinolytic functional units; B) surface adhesive units; and C) units containing zwitterionic structures. This not only enables a uniform and robust functional coating on the surface of medical biomaterials, but also allows for efficient regulation of antithrombotic functions through multiple mechanisms to meet the specific needs of different medical devices. Furthermore, the preparation process of this antithrombotic polymer and its application as a coating for medical devices are simpler, facilitating efficient modification of devices with various shapes and special structures.

This invention belongs to the field of pharmaceutical technology and relates to platelet aggregation inhibitors, their preparation methods, and applications. This invention provides compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates, wherein R1, R2, and n are as described in the claims and specification. This invention also provides intermediates for preparing compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates. The compounds of general formula I of this invention, their pharmaceutically usable salts, tautomers, pharmaceutically usable solvates, or pharmaceutical compositions thereof have platelet-inhibiting activity and can be used to prepare platelet aggregation inhibitors, which can be used to treat thromboembolic diseases, especially cerebral infarction.

Devices and methods for occluding the left atrial appendage (LAA) are described. [Solution] The device removes the LAA from the bloodstream, particularly in patients with atrial fibrillation, to prevent blood from forming a blood clot within the LAA and subsequently causing embolism. The implantable device is delivered into the LAA via transcatheter delivery and fixed within the LAA. The implant comprises an expandable compliant frame and an expandable, shape-conforming tubular foam body. The device may have an antithrombotic cover at its proximal end. The frame may have recapture struts that are inclined radially outward from a central hub. The frame may have axially extending sidewall struts, and adjacent pairs of sidewall struts may be joined at one or more vertices. Anchors extend from the frame, penetrate into the foam, and engage with the tissue.

This invention discloses a traditional Chinese medicine composition for treating cerebrovascular diseases, belonging to the technical field of cerebrovascular disease drugs. The composition comprises the following components in parts by weight: 10-30 parts of Polygonatum sibiricum, 6-15 parts of Rosa laevigata, 6-12 parts of Euonymus alatus, 6-15 parts of Polygonum cuspidatum, 3-9 parts of Acorus tatarinowii, 3-10 parts of Alpinia oxyphylla, 3-6 parts of Aralia elata septum, 3-10 parts of Rhodiola rosea, 3-10 parts of Bletilla striata, and 1-6 parts of Cinnamomum cassia. This invention addresses the pathological characteristics of cerebrovascular diseases, including long disease courses, multiple risk factors, and involvement of multiple target organs. Through the systematic combination of ten herbs, it can simultaneously achieve cerebrovascular protection, nerve function repair, and protection against multi-organ damage. Animal experiments and clinical observations have confirmed that this composition can significantly improve patients' neurological deficit scores, reduce the incidence of complications, and has clear preventive and therapeutic effects on secondary complications such as stress ulcers and renal impairment, while also possessing antithrombotic and hemostatic properties and high safety.

The application provides a directional thrombolytic pro-endothelialization composite small-caliber artificial blood vessel and a preparation method thereof. The method activates and chemically modifies the surface of an expanded polytetrafluoroethylene (ePTFE) artificial blood vessel through plasma treatment, introduces active carboxyl groups and covalently grafts a pro-endothelial adhesion polypeptide REDV; then, by using the strong adhesion of a polydopamine (PDA) coating, nano-hydrogel particles loaded with thrombolytic drugs t-PANPs are fixed on the inner surface of the blood vessel. The application actively recruits endothelial cells by the bottom layer of the REDV polypeptide, and at the same time, realizes on-demand and controlled release of t-PA for thrombolysis by the upper layer of the nano-hydrogel, thereby solving the problems of easy thrombosis and intimal hyperplasia of the small-caliber artificial blood vessel. The preparation process condition is mild, the performance is stable, the synergistic effect of antithrombosis and pro-endothelialization is realized, and the application has a good clinical application prospect.

This invention discloses a dual-network self-healing acellular bio-based artificial coronary artery bypass graft, belonging to the field of biomedical materials and tissue engineering technology. It comprises an interpenetrating first and second network; the first network is a natural animal-derived small-diameter acellular vascular matrix; the second network is a cross-linked polymer network containing at least one dynamically reversible bond selected from hydrazone bonds, Schiff base bonds, hydrogen bonds, metal coordination bonds, ionic bonds, disulfide bonds, and borate ester bonds. This invention also discloses a method for preparing the artificial coronary artery bypass graft. This invention achieves synergy between mechanical compliance matching and self-healing function through the dual-network interpenetrating structure. A functionalized modification layer can also be applied to the inner surface of the lumen to accelerate in-situ endothelialization and inhibit thrombus formation. This artificial coronary artery bypass graft possesses good mechanical compliance, rapid self-healing ability, and excellent antithrombotic and endothelialization-promoting properties, significantly improving the long-term patency rate of small-diameter artificial blood vessels, and is suitable for coronary artery bypass grafting.

This invention relates to the field of traditional Chinese medicine preparation technology, specifically to a blood-activating and meridian-clearing traditional Chinese medicine composition with agarwood as the principal ingredient. The composition comprises the following raw materials in parts by weight: 5-15 parts modified agarwood complex, 40-60 parts compound extract powder, 1-3 parts broken-cell-wall scorpion powder, 20-50 parts filler, and 0.5-2 parts lubricant. This invention improves the efficient release of the effective components of agarwood as the principal ingredient by using the modified agarwood complex, ensuring the stability of the core efficacy of agarwood and extending the retention time of its core components. The addition of compound extract powder scientifically combines blood-activating and blood-nourishing herbs, ensuring powerful meridian clearing while replenishing qi and blood, reducing the side effects of long-term medication, and improving patient safety. The broken-cell-wall scorpion powder reduces the risk of sensitization and poisoning, breaking the cell walls of the scorpion to fully release the core analgesic peptides and antithrombotic peptides, thus improving gastrointestinal absorption efficiency.

A medical device, which includes: a base material; an antithrombogenic layer including a polymer fixed to the base material, in which the polymer includes: a structural unit a derived from a first monomer bonded to the base material and including a reactive group that reacts with a hydroxyl group or a carboxyl group and an ethylenically unsaturated group; a structural unit B including a polymer chain including a structural unit b derived from a first antithrombogenic monomer including a carboxyl group and an ethylenically unsaturated group, and including a terminal of the polymer chain bonded to the structural unit a; and a structural unit C derived from a copolymer including a structural unit c1 derived from a second monomer including an amino group and bonded to the structural unit b and a structural unit c2 derived from a second antithrombogenic monomer.

The application discloses a composite drug sustained-release system based on a biomimetic glycocalyx coating and a medical catheter. The sustained-release system comprises, in sequence, an adhesion layer, a drug storage layer and a biomimetic glycocalyx coating arranged on the surface of a base. The adhesion layer is formed by in-situ polymerization of polyphenols. The drug storage layer embeds active drugs through hydrophobic or amphiphilic polymers. The biomimetic glycocalyx coating simulates the structure of vascular endothelium and is formed by cross-linking of modified polyethylene glycol and biological macromolecules through polyphenols and metal ions. The application can realize self-repairing of damage by using the double cross-linking network of the biomimetic glycocalyx coating, and can synergistically regulate drug release kinetics through a high hydration physical barrier and the storage layer, thereby significantly reducing the friction coefficient of intervention, and also endowing the medical catheter with properties such as antithrombosis and drug sustained release, effectively inhibiting initial burst release of drugs and prolonging the release period, and significantly improving the mechanical resistance, biocompatibility and safety of the medical catheter.

This invention belongs to the fields of medicinal chemistry, glycochemistry, and biomedicine, and provides a fucoidan-based heparin pentasaccharide, its preparation method, and its applications. The preparation method involves the chemical linkage and purification of sulfated azidoethyl-α-L-pyranoside with alkyne-based heparin pentasaccharide to obtain the target product. This compound exerts anticoagulant and antithrombotic effects by potently inhibiting the intrinsic coagulation factor X enzyme complex (FXase). Its APTT prolongation and FXase inhibitory activity are significantly superior to heparin pentasaccharide, and it significantly reduces the risk of bleeding at equivalent antithrombotic doses. It can be used in the development of drugs or functional foods for thrombotic cardiovascular and cerebrovascular diseases.

The application belongs to the technical field of biological medicine, and discloses a thrombolytic composition containing plant extracts and biological enzymes, and a preparation method and application thereof. The composition contains the following components in parts by weight: natto kinase 50-200 parts; lumbrukinase 10-50 parts; angelica extract 10-100 parts; turmeric extract 10-100 parts; brown algae extract 5-50 parts; protective agent: mannitol 0.2-0.5 parts, edible gelatin 0.5-5 parts, and sodium bicarbonate 0.1-2 parts. The application realizes the synergistic antithrombotic effect of multiple mechanisms and multiple targets through the direct thrombolytic effect of natto kinase and lumbrukinase, and the anti-platelet aggregation, anti-inflammatory and anticoagulation effects of angelica, turmeric and brown algae, and improves the oral bioavailability. The ingredients with the same origin of medicine in the formula help to improve the microcirculation and protect the vascular endothelium. Compared with traditional chemical drugs, the composition has higher safety and smaller side effects, and is suitable for long-term prevention and rehabilitation.

The invention discloses a recombinant engineering bacterium, a preparation method thereof and application of the recombinant engineering bacterium in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The recombinant engineering bacterium is prepared by taking salmonella typhimurium with relA and spoT gene mutations as a carrier and introducing a recombinant plasmid containing a thrombolytic enzyme coding gene into the carrier. The invention provides a recombinant engineering bacterium with biological safety, the recombinant engineering bacterium has high thrombus targeting property under a dynamic blood flow condition, various thrombus models can be specifically targeted, and the concentration of the recombinant engineering bacterium in thrombus tissues can reach more than ten thousand times of the concentration of normal tissues such as spleen, liver and the like through bacterium proliferation. Through mediated thrombus targeted therapy, thrombus can be effectively dissolved, and revascularization is achieved. The invention provides a more effective and safer treatment strategy for diseases caused by thrombus, such as myocardial infarction, cerebral apoplexy, pulmonary embolism and the like.

The application belongs to the technical field of biological medicine, and particularly relates to a Buthus martensii Karsch (Buthus martensii Karsch) oligopeptide and application thereof in preparation of anti-platelet and anti-thrombus drugs or compositions. Buthus martensii The application discloses an anti-platelet oligopeptide discovered by combining an active-oriented separation with computer virtual screening based on a Karsch transcriptome database. The oligopeptide can not only inhibit platelet aggregation, but also effectively inhibit platelet adhesion and expansion. In a thrombus model experiment in vivo, the Buthus martensii Karsch oligopeptide discovered by the application can well inhibit FeCl3-induced carotid artery thrombosis of a mouse. Meanwhile, it is found that the Buthus martensii Karsch oligopeptide does not have obvious bleeding tendency. In conclusion, the Buthus martensii Karsch oligopeptide can be used as an anti-platelet aggregation and anti-thrombus drug to play a certain positive role in the prevention and treatment of thrombotic diseases.

This invention relates to a recombinant hirudin fusion protein with collagen affinity, its preparation method, and its applications. The fusion protein is a recombinant hirudin fusion protein incorporating a collagen-binding domain (CBD). The fusion protein of this invention possesses affinity for type I and type III collagen, and can inhibit thrombin activity to exert an anticoagulant effect. Furthermore, it can bind well to collagen-based composite materials, making it suitable for use in cardiovascular implants such as heart valves, cardiac occluders, dialysis membranes, oxygenation membranes, artificial blood vessels, and vascular stents, as well as in extracorporeal circulation and blood purification devices, enhancing anticoagulant and antithrombotic effects.

This invention relates to the field of biomimetic materials, and particularly to a blood contact material, a biomimetic coating, its construction method, and its applications. The active ingredient in the blood contact material is formed by polymerizing vinyl lysine, oligoethylene glycol methyl ether methacrylate, and vinyl dopamine. The blood contact material is dissolved in a first buffer solution with a pH value of 7.5-9 to obtain a coating solution. The substrate is immersed in the coating solution for a first time and then removed, allowing the substrate surface to be covered with an intermediate coating. The polymerized poly(oligoethylene glycol methyl ether methacrylate) segments can form a dense hydration layer providing antifouling functionality. The polylysine segments can specifically bind plasminogen and tissue-type plasminogen activator, dissolving primary thrombi. The polydopamine segments have adhesive properties, improving the substrate's versatility and facilitating coating formation. The blood contact material can mimic the antifouling and fibrinolytic functions of the vascular endothelium, contributing to a comprehensive antithrombotic effect.

This invention relates to an antithrombotic conjugate formed by conjugating a terpolymer with an active anticoagulant fragment, wherein the terpolymer comprises: A) an inert anticoagulant unit; B) a graft unit with reactive groups; and C) a unit that adheres to a substrate. By utilizing the synergistic effect of the active anticoagulant fragment, such as a heparin fragment, and the inert anticoagulant unit simultaneously present in the antithrombotic conjugate, multi-dimensional and multifunctional anticoagulant effects can be achieved, thus matching the different usage scenarios and anticoagulant requirements of blood-contact medical devices in clinical practice. When this antithrombotic conjugate is coated onto a substrate surface, the unit that adheres to the substrate acts as an adhesive layer, achieving excellent adhesion and long-lasting coating performance, maintaining function in a flowing blood environment.

Medical articles formed from ionically bonding an ionic polymer and an active agent provide enhanced properties. The ionic polymer may be one or more of an anionic polymer, a cationic polymer, and a zwitterionic polymer. The device may also include a nonionic polymer. Medical articles herein have antimicrobial, anti-fouling, and / or antithrombotic characteristics.